Ownership and insider activity for Cerus Corporation (CERS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
Price
| Price | $2.53 |
| Market Cap | $510M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-17 | Jensen Chrystal | S-Sale | 30,000 | $90K |
| 2026-07-16 | Jayaraman Vivek K | S-Sale | 16,666 | $53K |
| 2026-06-30 | Green Kevin Dennis | A-Award | 63,600 | |
| 2026-06-30 | Green Kevin Dennis | S-Sale | 33,676 | $99K |
| 2026-07-01 | Jayaraman Vivek K | A-Award | 554,529 | |
| 2026-06-30 | Jayaraman Vivek K | A-Award | 80,000 | |
| 2026-06-30 | Jayaraman Vivek K | S-Sale | 42,359 | $125K |
| 2026-07-01 | Jayaraman Vivek K | A-Award | 369,686 | |
| 2026-06-30 | Jensen Chrystal | A-Award | 55,000 | |
| 2026-06-30 | Jensen Chrystal | S-Sale | 24,329 | $72K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.6M | $13.7M | $28.9M | $35.0M | $36.6M | $48.8M | $35.6M | $11.6M | $20.3M | $20.0M |
| Short-term Investments | $49.1M | $47.0M | $88.7M | $50.7M | $97.0M | $80.6M | $66.6M | $54.2M | $60.2M | $62.9M |
| Receivables | $6.9M | $12.4M | $8.8M | $16.9M | $21.2M | $25.1M | $34.4M | $35.5M | $29.8M | $30.4M |
| Inventory | $12.5M | $14.5M | $13.5M | $19.5M | $23.3M | $26.8M | $29.0M | $39.9M | $38.1M | $56.1M |
| Total Current Assets | $94.1M | $89.9M | $146.9M | $128.1M | $183.4M | $187.1M | $170.1M | $144.4M | $152.0M | $174.4M |
| Property, Plant & Equipment | $3.0M | $2.1M | $8.1M | $29.0M | $27.0M | $25.2M | $23.5M | $19.4M | $15.5M | $19.3M |
| Goodwill | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M |
| Intangible Assets | $738000 | $536000 | $334000 | $132000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $103.5M | $98.2M | $163.5M | $165.5M | $221.4M | $237.5M | $218.1M | $197.7M | $200.9M | $221.9M |
| Accounts Payable | $8.6M | $11.0M | $18.6M | $22.2M | $24.2M | $35.6M | $33.0M | $23.8M | $21.7M | $28.0M |
| Short-term Debt | $6.9M | 0 | $7.9M | $5.0M | $8.5M | $14.7M | $56.2M | $20.0M | $19.3M | $43.3M |
| Total Current Liabilities | $26.9M | $23.1M | $52.7M | $50.3M | $60.0M | $78.6M | $117.1M | $67.5M | $63.6M | $100.8M |
| Long-term Debt | $12.4M | $29.8M | $22.0M | $39.4M | $39.6M | $54.7M | $13.6M | $59.8M | $64.9M | $40.5M |
| Total Liabilities | $45.7M | $59.3M | $78.9M | $108.5M | $117.6M | $151.9M | $149.5M | $144.3M | $144.0M | $156.9M |
| Retained Earnings | -$660.7M | -$721.3M | -$778.9M | -$850.1M | -$910.0M | -$964.3M | -$1.01B | -$1.04B | -$1.07B | -$1.08B |
| Total Equity | $57.8M | $38.9M | $84.5M | $57.1M | $103.8M | $84.6M | $67.6M | $52.6M | $56.1M | $64.2M |
| Total Debt | $19.4M | $29.8M | $29.9M | $64.5M | $66.9M | $87.6M | $87.2M | $96.0M | $98.1M | $96.9M |
| Net Debt | -$52.3M | -$30.9M | -$87.7M | -$21.3M | -$66.7M | -$41.8M | -$14.9M | $30.1M | $17.6M | $14.1M |
| Working Capital | $67.2M | $66.8M | $94.2M | $77.8M | $123.5M | $108.5M | $53.1M | $76.9M | $88.4M | $73.6M |
Financial Health
| Debt / Equity | 1.10 |
| Current Ratio | 1.83 |
Profitability
| Return on Equity | -10.31% |
| Return on Invested Capital | -1.06% |
| Return on Assets | -3.31% |
| Gross Margin | 52.05% |
| Operating Margin | -0.73% |
| Net Margin | -3.06% |
Related companies: CVRX · MASS · NPCE · QTRX · RXST · SENS · SGHT
Explore sector: Healthcare · Medical - Devices
More sections of CERS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks